Medical Oxygen News
-
BioIntelliSense Launches Patented, FDA-cleared Pulse Oximetry (SpO2) Sensor Technology that Addresses Skin Pigmentation and Motion Monitoring Challenges
Breakthrough pulse oximetry (SpO2 ) optical sensor solution offers medical-grade accuracy of oxygen level measurement across skin tones and while in motion Patented SpO2 sensor chipset, integrated processing and reference design capability to power the next generation of medical and consumer wearable devices BioIntelliSense, a continuous health monitoring and clinical intelligence company, ...
-
Redox Check-Up
A new Service for the Medical Practice Reactive Oxygen Species (ROS) represent one of the most abundant types of free radicals. In physiological conditions ROS levels are regulated by a fine equilibrium namely RedOx balance. When ROS production outperforms the physiological ability to counteract the deleterious effects of these reactive species a condition known as oxidative stress (OS) ...
By H & D S.r.l.
-
Role of oxygen generator in the epidemic period of coronavirus disease
Why is the oxygen generator important? Oxygen is a life-saving therapeutic gas, which is often used to treat patients with severe pneumonia and other respiratory diseases. Oxygen generator is an electric medical equipment. It first inhales air, removes nitrogen, then generates a continuous oxygen source, and delivers concentrated oxygen to patients who need respiratory support in a controlled ...
-
Presentation at ECCMID
Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, presented the sub-group analysis from its Phase 2, SG016 study on Saturday 23 April in an oral presentation at the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), held in Lisbon, ...
-
Third Pole Therapeutics Closes $25M Financing - eNOfit Wearable Device Now Ready for Clinical Trials
eNOfit™, Third Pole’s novel nitric oxide mobile-wearable device designed to provide “on-the-go” treatment for patients suffering from severe COPD and ILD, to enter clinical trials in the second half of this year Funding will support device optimization and clinical trials; Pivotal trial data expected in the second half of 2023 Third Pole Therapeutics, a privately ...
-
BenevolentAI Achieves Second Major Collaboration Milestone With Novel Idiopathic Pulmonary Fibrosis Target Selected For AstraZeneca’s Portfolio
Novel target for idiopathic pulmonary fibrosis was discovered using BenevolentAI’s AI-drug discovery platform and experimentally validated by AstraZeneca Announcement represents the second collaboration milestone following the addition of a novel chronic kidney disease target to AstraZeneca’s portfolio in Q1 2021 London, 15 December 2021: BenevolentAI, a leading ...
By Benevolent
-
World Health Organization Recognizes MediPines AGM100 in 2021 Compendium for Innovative Health Technologies
ORANGE COUNTY, Calif., Sept. 21, 2021 /CNW/ — The World Health Organization (WHO) has just featured MediPines AGM100®, pulmonary gas exchange analyzer as an innovative technology in their 2021 compendium, “WHO compendium of innovative health technologies for low-resource settings”. This year’s annual assessment report provided much needed global awareness for ...
By MediPines
-
Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19
Eli Lilly and Company (NYSE: LLY), Vir Biotechnology, Inc. (NASDAQ: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced topline data from the expanded Phase 2 BLAZE-4 trial studying low-risk adult patients with mild to moderate COVID-19. Results showed that investigational bamlanivimab (LY-CoV555) 700 mg co-administered with VIR-7831 (also known as GSK4182136) 500 mg demonstrated a 70 ...
-
ACTT-2 trial results published in the New England Journal of Medicine validate baricitinib’s efficacy in combination with remdesivir in hospitalised COVID-19 patients
Peer-reviewed resultsfrom the Adaptive COVID-19 Treatment Trial (ACTT-2) published in the New England Journal of Medicine showed that baricitinib in combination with remdesivir reduces recovery time, improves clinical status and demonstrates a trend towards a decrease in mortality in hospitalised COVID-19 patients with pneumonia. Those who took both drugs had a median time to recovery of seven ...
By Benevolent
-
Study Shows Significant Reduction in Oxygen Expenditures with Conversion to VOCSN
NEW Oxygen Study Ventec Life Systems recently published new research showing oxygen expenditures decreasing by 75% for a long term care facility after conversion to VOCSN Multi-Function Ventilator. With recent news about oxygen shortages impacting hospitals and facilities using ventilators, this research is especially timely. The facility studied realized annualized savings of over $16,000 for ...
-
Dexamethasone reportedly part of President Trump’s Treatment
As part of the standard of care treatment protocol, President Trump received dexamethasone for his COVID-19 disease, highlighting the value of dexamethasone. Dexamethasone has been widely used since its initial approval in 1958 in treating acute disease. The use of higher dexamethasone doses, with potentially additional and desired immunological effects, is limited due the presence of toxic ...
-
DOD to Fund a Multi-Center Randomized Clinical Trial of COVID-19 Treatment with ExThera’s Seraph 100 Blood Filter
After encouraging preliminary results in the treatment of critically-ill COVID-19 patients at a military hospital in the United States and fourteen other hospitals in Europe, the Department of Defense has selected the Seraph®100 Microbind® Affinity Blood Filter (Seraph 100) as one of its main interventions in a pivotal, US-based randomized controlled trial. Financial support for the ...
-
Discover our support for critical medical care with the latest Expert Solutions magazine
Aimed at global medical gas suppliers, Issue 23 showcases our analytical products for essential assay and impurity measurements in a range of gases, including medical air and oxygen. Our key products featured are the SERVOPRO MultiExact 4100 and the SERVOPRO Chroma. The MultiExact 4100 provides simultaneous analysis of up to four gas streams, while the versatile Chroma has recently been updated ...
-
Profusa Receives CE Mark Approval to Market the Wireless Lumee® Oxygen Platform for Continuous, Real-Time Monitoring of Tissue Oxygen
Profusa, a digital health company that is pioneering the next generation of personalized medicine, today announced it has received Conformité Européenne (CE) Mark approval to market its Wireless Lumee® Oxygen Platform for continuous, real-time monitoring of tissue oxygen in patients with potential acute and/or chronic changes in tissue oxygen levels who may benefit from ...
-
Imtech: 130 million euro orders for innovation in the German care & cure market
Gouda - Imtech N.V. (technical services provider in Europe) announces that it has been awarded orders worth over 130 million euro in the care & cure sector in Germany. Innovation is the key word here. Imtech is involved in various innovations relating to ventilation, energy efficiency, ultra clean air in operating theatres and the use of medical gases. René van der Bruggen, CEO Imtech: ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you